Aa
A
A
Close
Avatar_universal
PARC rule .... Comments needed
“PARC rule” has been recently validated and published as
a stopping rule at week 12, using HBsAg and HBV DNA for
HBeAg-negative, genotype D patients treated with Peg-IFN
α-2a. According to this rule, we can identify early, with a NPV
of 100%, all CHB, HBeAg-negative, genotype D patients that
will not achieve SVR aer 48 or 96 weeks of treatment with
Peg-IFN α-2a [2]. e dierence between the results obtained
in our study (a NPV of 86% for absence of SVR and a PPV of
80% for those who achieved SVR) and the results published
in the validation trial conducted by Rijckborst et al, can be
explained by the inclusion in statistical analysis of both types
of patients, HBeAg positive and negative, and no stratication
of patients according to viral genotype
Cancel
1 Answers
Page 1 of 1
Avatar_universal
Hi, the rule tries to validate the duration of therapy with PEG-IFN. It states that in HBeAg-negative patients the sustained response to therapy is not present beyond 12 weeks. So, in these patients therapy beyond 12 weeks with PEG-IFN is not indicated. Regards.
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Your Answer
Avatar_universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
PARC rule .... Comments needed
Submit Answer
A
A
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
233488_tn?1310696703
Blank
Marathon Running Done Over Many Yea...
May 21 by John C Hagan III, MD, FACS, FAAOBlank
233488_tn?1310696703
Blank
New Article on Multifocal IOL vs &q...
May 21 by John C Hagan III, MD, FACS, FAAOBlank
748543_tn?1443740527
Blank
TMJ/TMJ The Connection Between Teet...
01/15 by Hamidreza Nassery , DMD, FICOI, FAGD, FICCMOBlank
Top Hepatitis Answerers
Avatar_m_tn
Blank
stef2011
Italy
Avatar_m_tn
Blank
StephenCastlecrag
Australia
Avatar_m_tn
Blank
sorte
Poland
Avatar_m_tn
Blank
Jatashankar
India
Avatar_m_tn
Blank
March06
Other
Avatar_f_tn
Blank
twinboys1girl4me